Thus, superior results were obtained for the administration of anti-CTLA4 therapy followed by hypofractionated radiotherapy, but the anti-PD-L1 therapy demonstrates the maximum potential of radio-sensitization of the tumor in case of concomitant administration. The gene discussed is CD274; the disease is neoplasm.